Citigroup Maintains Neutral on Health Catalyst, Lowers Price Target to $2.75
Benzinga Newsdesk 10 months ago
NewsPrice TargetAnalyst Ratings
Citigroup analyst Daniel Grosslight maintains Health Catalyst (NASDAQ:HCAT) with a Neutral and lowers the price target from $3.25 to $2.75.
Citigroup analyst Daniel Grosslight maintains Health Catalyst (NASDAQ:HCAT) with a Neutral and lowers the price target from $3.25 to $2.75.